Garniglipt 50 Tablet contains Vildagliptin 50mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system. This mechanism increases insulin secretion from pancreatic beta cells and decreases glucagon release from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Garniglipt 50 is indicated as monotherapy in patients inadequately controlled by diet and exercise alone or as an adjunct to other antidiabetic agents such as metformin, sulfonylureas, or insulin. The tablet is typically administered once or twice daily, with or without food, as directed by a healthcare professional. Common adverse effects may include headache, dizziness, nasopharyngitis, and gastrointestinal disturbances, though it is generally well tolerated. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose levels and periodic assessment of renal function are recommended during therapy. Garniglipt 50 should be used as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and exercise.